治疗下丘脑性肥胖的药物研究进展  

Progress in drug therapy for hypothalamic obesity

作　　者：张沥元 杜函泽 潘慧[1] ZHANG Liyuan;DU Hanze;PAN Hui(Department of Endocrinology,Key Laboratory of Endocrinology of National Health Commission,Peking Union Medical College Hospital,CAMS&PUMC,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院、北京协和医院内分泌科、国家卫生健康委员会内分泌重点实验室,北京100730

出　　处：《基础医学与临床》2024年第5期729-732,共4页Basic and Clinical Medicine

基　　金：中央高水平医院临床科研专项青年项目(2022-PUMCH-A-154)。

摘　　要：下丘脑性肥胖(HO)是一种复杂而罕见的疾病,影响大脑中能量摄入和支出调节通路以及自主神经系统和外周激素信号的调节。目前药物治疗主要通过刺激交感神经兴奋和脂肪组织产热,从而以增加脂肪分解和能量消耗的方式抑制体质量的快速增长。此外,部分药物还可作用于大脑奖励中心,抑制HO患者过度摄食。本文介绍了外源性催产素(OXT)、芬特明/托吡酯合剂(Ph/T)、特索芬辛、赛美拉肽等新近研发药物的临床获益数据、不良反应和应用前景。Hypothalamic obesity(HO)is a complicated and uncommon disease affecting multiple regulatory pathways of energy intake and metabolism in the brain,regulation of the autonomic nervous system and peripheral hormonal signaling.Currently,drug treatment mainly involves stimulating sympathetic nerve excitation and fat tissue thermogenesis,thereby inhibiting rapid weight gain by increasing fat breakdown and energy consumption.In addition,some drugs can also act on the reward center of the brain to inhibit excessive food intake in HO patients.This article systematically introduces the clinical benefit data,adverse reactions,and application prospects of newly developed drugs such as oxytocin(OXT),phentermine and topiramate(Ph/T),tesofensine,setmelanotide,etc.

关 键 词：肥胖 脑肿瘤 下丘脑损伤 能量稳态 药物治疗 

分 类 号：R589.2[医药卫生—内分泌]